Mass Treatment T Solium Community Study

Intestinal Parasitism Clinical Trial

Official title:

The Effect of a Single Control Intervention in the T Solium Life Cycle

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00138359
• Other study ID #: 04-043
• Status: Terminated
• Phase: N/A
• First received: August 26, 2005
• Last updated: August 26, 2010
• Start date: December 2004
• Est. completion date: January 2005

Study information

• Verified date: December 2006
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

Investigators from Cayetano Heredia University and Johns Hopkins University are doing this study. They want to see how people and pigs get infected with a parasite, called cysticercus (known as "pig triquina"). Cysticercus attacks the meat of pigs and the brains of people. In the intestine, the parasite is known as "solitaria". This study is to see how treatment in both people and pigs works to control the disease.

Description:

This is a prospective intervention study to determine the efficacy and persistence of effect over time of a single, chemotherapy intervention in both the human and porcine population. Four villages will be selected to be treated against T solium adult (in humans) and larval forms (in pigs), and two villages will receive no intervention and will serve as control villages. Pigs in control villages will be followed during 3 months only, and then the human and porcine populations will receive the intervention treatment. The effect of this intervention will be measured by the prevalence of infection in pigs and parasitic burden of infected pigs at month 3, 6, 9, and 12.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4200
• Est. completion date: January 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• All consenting individuals older than two years living in the study villages (6 endemic communities of the Northern coast of Peru)

Exclusion Criteria:

• Pregnancy (for antiparasitic treatment only).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Intestinal Diseases, Parasitic
• Intestinal Parasitism

Intervention

Drug:
• Niclosamide

Locations

Country	Name	City	State
Peru	Universidad Peruana Cayetano Heredia	Lima

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Peru,